Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2009

01-09-2009 | Original Article

Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women

Authors: S. Bharadwaj, A. G. T. Naidu, G. V. Betageri, N. V. Prasadarao, A. S. Naidu

Published in: Osteoporosis International | Issue 9/2009

Login to get access

Abstract

Summary

Current treatments for postmenopausal osteoporosis suffer from side effects. Safe and natural milk proteins, ribonuclease, and lactoferrin promote formation of new capillaries and bone formation. A ribonuclease-enriched lactoferrin supplement studied here, demonstrates significant reduction in resorption and increase in formation, towards restoring the balance of bone turnover within 6 months.

Introduction

Osteoporosis, a major health issue among postmenopausal women, causes increased bone resorption and reduced bone formation. A reduction in angiogenesis could also contribute to this imbalance. Current treatments such as hormone replacement therapy and bisphosphonates have drawbacks of severe side effects. Milk ribonuclease (RNase) is known to promote angiogenesis and lactoferrin (LF) to stimulate bone formation by osteoblasts. We examine the effect of ribonuclease-enriched lactoferrin supplement on the bone health of postmenopausal women.

Methods

A total of 38 healthy, postmenopausal women, aged 45 to 60 years were randomized into placebo or RNAse-enriched-LF (R-ELF) supplement groups. The bone health status was monitored by assessing bone resorption markers, serum N-telopeptides (NTx), and urine deoxypyridinoline (Dpd) crosslinks and serum bone formation markers, bone-specific alkaline phosphatase (BAP), and osteocalcin (OC).

Results

R-ELF supplementation demonstrated a decrease in urine Dpd levels by 14% (19% increase for placebo) and serum NTx maintained at 24% of the baseline (41% for placebo), while serum BAP and OC levels showed a 45% and 16% elevation (25% and 5% for placebo).

Conclusions

R-ELF supplementation demonstrated a statistically significant reduction in bone resorption and increase in osteoblastic bone formation, to restore the balance of bone turnover within a short period.
Literature
1.
Melton U, Chrischilles EA, Cooper C et al (1992) How many women have osteoporosis? J Bone Miner Res 7:1005–1010PubMed
2.
Melton LJ 3rd, Atkinson EJ, O’Connor MK et al (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915PubMedCrossRef
3.
Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11:545–560PubMedCrossRef
4.
Herrington DM, Howard TD (2003) Hormone therapy and heart disease: from presumed benefit to potential harm. N Engl J Med 349:5519–5521CrossRef
5.
Makins R, Ballinger A (2003) Gastrointestinal side effects of drugs. Expert Opin Drug Safety 2:421–429CrossRef
6.
Kawakami H (2005) Biological significance of milk basic protein (MBP) for bone health. Food Sci Technol 11:1–8CrossRef
7.
Aoe S, Toba Y, Yamamura J et al (2001) Controlled trial of the effects of milk basic protein (MBP) supplementation on bone metabolism in healthy adult women. Biosci Biotechnol Biochem 65:913–918PubMedCrossRef
8.
Yamamura J, Aoe S, Toba Y et al (2002) Milk basic protein (MBP) increases radial bone mineral density in healthy adult women. Biosci Biotechnol Biochem 66:702–704PubMedCrossRef
9.
Morita Y, Matsuyama H, Serizawa A et al (2008) Identification of angiogenin as the osteoclastic bone resorption-inhibitory factor in bovine milk. Bone 42:380–387PubMedCrossRef
10.
Glowacki J (1998) Angiogenesis in fracture repair. Clin Orthop 355S:S82–S89CrossRef
11.
12.
Cornish J, Callon KE, Naot D et al (2004) Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vitro. Endocrinology 145:4366–4374PubMedCrossRef
13.
14.
Naidu AS (2008) Angiogenin complexes (ANGex) and uses thereof. US Patent Application No. 20080255340
15.
Naidu AS (2008) Immobilized angiogenin mixtures and uses thereof. US Patent Application No. 20080254018
16.
Gomez B Jr, Ardakani S, Ju J et al (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41(11):1560–1566PubMed
17.
Delmas PD, Stenner D, Wahner HW et al (1983) Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone gla-protein. J Lab Clin Med 102:470–476PubMed
18.
Clemens JD et al (1997) Evidence that serum NTx (collagen type I N-telopeptides) can act as immunochemical marker of bone resorption. Clin Chem 43:2058–2063PubMed
19.
Delmas PD, Schlemmer A, Gineyts E et al (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured in iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639–644PubMedCrossRef
20.
Heinegard D, Tiderstrom G (1973) Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 43:305PubMedCrossRef
21.
Zar JH (1999) Biostatistical analysis, 4th edn. Prentice Hall, NJ, p 475
22.
Eastell R, Mallinak N, Weiss S et al (2000) Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 15:594–598PubMedCrossRef
23.
Scariano JK, Glew RH, Bou-Serhal CE et al (1998) Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 23:471–477PubMedCrossRef
24.
Gertz BJ, Clemens JD, Holland SD et al (1998) Application of a new serum assay for type i collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102–106PubMedCrossRef
25.
Clemens JD, Herrick MV, Singer FR et al (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058–2063PubMed
26.
Prestwood KM, Thompson DL, Kenny AM et al (1999) Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 84:179–183PubMedCrossRef
27.
Rosen HN, Parker RA, Greenspan SL et al (2004) Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int 74:415–423PubMedCrossRef
28.
Ton FN, Gunawardene SC, Lee H et al (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464–470PubMedCrossRef
29.
Greenspan SL, Parker R, Ferguson L et al (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Mineral Res 13:1431–1438CrossRef
30.
Garnero P, Shih WJ, Gineyts E et al (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700PubMedCrossRef
31.
Reid IR, Lucas J, Wattie D et al (2005) Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90:5212–5216PubMedCrossRef
32.
Chen P, Satterwhite JH, Licata AA et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef
33.
Suzuki YA, Lonnerdal B (2002) Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol 80:75–80PubMedCrossRef
34.
Grey A, Banovic T, Zhu Q et al (2004) The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18:2268–2278PubMedCrossRef
35.
Shestenko OP, Nikonov SD, Mertvetsov NP (2001) Angiogenin and its functions in angiogenesis. Mol Biol 35:294–314CrossRef
36.
Chesnut CH III, McClung MR, Ensrud KE et al (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144–152PubMedCrossRef
37.
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedCrossRef
38.
Lufkin EG, Whitaker MD, Nickelsen T et al (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747–1754PubMedCrossRef
39.
Meunier PJ, Slosman DO, Delmas PD et al (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066PubMedCrossRef
40.
Jamal SA, Cummings SR, Hawker GA (2004) Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 19:1512–1517PubMedCrossRef
41.
Cosman F (2006) Anabolic therapy for osteoporosis: parathyroid hormone. Curr Rheumat Rep 8:63–69CrossRef
42.
Asirvatham S, Sebastian C, Thadani U (1998) Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf 19:23–44PubMedCrossRef
43.
Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for two years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRef
44.
Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703PubMedCrossRef
45.
Hochberg MC, Greenspan S, Wasnich RD et al (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592PubMedCrossRef
Metadata
Title
Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women
Authors
S. Bharadwaj
A. G. T. Naidu
G. V. Betageri
N. V. Prasadarao
A. S. Naidu
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 9/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-0839-8

Other articles of this Issue 9/2009

Osteoporosis International 9/2009 Go to the issue

Short Communication

Factors predicting osteoporosis treatment initiation in a regionally based cohort

Original Article

External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures

Original Article

Effectiveness of a community-based osteoporosis education and self-management course: a wait list controlled trial

Review

Is bone quality associated with collagen age?

Original Article

Comparison of QCT-derived and DXA-derived areal bone mineral density and T scores

Original Article

Spinal deformity index (SDI) is a good predictor of incident vertebral fractures